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Abstract—The left atrial appendage (LAA) is a small, finger-
like extension of the left atrium and its exclusion is used as a
treatment strategy to prevent ischemic stroke. Existing holdfast
devices may damage the tissue, are unisized and not adjustable.
A novel holdfast device for LAA exclusion devoid of these
shortcomings was designed and 3D-printed using the Selective
Laser Sintering (SLS) technology with polyamide powder and
tested it on animal model. We selected the SLS 3D printing
technology due to its wid14e availability and low production
costs which could provide on-site 3D printing for specific
patient. The purpose of this study was to evaluate the
biocompatibility of the reported holdfast device and compare
the histological results obtained for local tissue reactions to
thoseobtained for an established graftingmaterial. Thirty swine
subdivided into two groups were examined. The LAAexclusion
device was implanted and was either coated with a polyester
vascular implant or not coated at all and the histological
response to the device’s presence was evaluated which is a
standard approach to test the device biocompatibility. In all
cases, complete occlusion was seen without any pathological
findings during the incubation time. In both groups, the surface
of the atrium under a holdfast devicewas smooth and shiny and
had no clots. The foreign body reaction of the LAA holdfast
device made of polyamide powder was insignificantly lower
compared to thepolyester graft.Thus, it fulfils the parameters of
biocompatibility at the highest degree, andmakes it suitablema-
terial for the manufacturing of LAA holdfast devices.
Keywords—Stroke prevention, 3D printing, Cardiovascular
surgery, Atrial fibrillation, Left atrium.
INTRODUCTION
The left atrial appendage (LAA) is a small, finger-
like extension of the left atrium protruding from its
lateral or inferolateral wall with a narrow junction to
the venous component of the left atrium (Fig. 1a).
Embryologically, it is a remnant of the original left
atrium, and in contrast to the smooth walled venous
component of the left atrium, it is richly trabeculated
(Fig. 1b). The LAA is considered largely nonfunc-
tional. However, its complex morphology, trabecula-
tions, narrow ostium and scant blood flow make the
LAA a prime cardiac site for thrombus formation.
Patients with atrial fibrillation are particularly at risk,
and complications may lead to ischemic stroke.2,31
Atrial fibrillation is the most frequent type of cardiac
arrhythmia, although it maintains a low rate of suc-
cessful treatment.9 Patients with atrial fibrillation have
a five-fold greater risk for developing ischemic stroke
due to formation of blood clots in their LAAs.30 This
may occur incidentally or rapidly (within 6 h of onset
of symptoms) in some cases.6 The most common
method for preventing ischemic stroke is antithrom-
botic treatment. However, pharmacological treatments
pose a risk of major bleeding, including intracranial
hemorrhage.4 Additionally, antithrombotic therapy is
not recommended for some patients and may even be
prohibited as a primary treatment modality in some
cases.4,21,24 A new approach to solve the abovemen-
tioned issues would consist of obliterating the LAA,
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which remains the most frequent source of clot for-
mation within the heart.7,19,20,22
To date, there are several devices on the market that
can successfully occlude the LAA.7,13,18–20,22,23 There
are two categories of LAA closure devices which are
designed to close the base of the LAA and prevent
blood flow to circulate through it (thus excluding the
LAA from the circulatory system). They are classified
by their method of implantation. There are holdfasts
which are introduced by performing a thoracotomy to
close the LAA from the outside, and excluders, which
are placed by using endovascular techniques to close
the LAA from the inside. The advantage of the hold-
fasts is their great efficiency, whereas the latter have a
less invasive procedure (the procedure is performed
under local anesthesia with transcatheter and no sur-
gical opening of the chest).5
There are several existing holdfast devices on the
market, however each of them has some disadvantages.
Some of them (particularly staplers) are designed to
pierce the base of the LAA during implantation.
However, this initial step damages the tissue and
interrupts the continuity of the left atrial wall and leads
to blood leakage.14 Moreover, currently used devices
do not allow post-insertion adjustments after release
from the applicator. Finally, they are produced in a
single size without possibility for modifications for the
specific anatomy of a given patient.8 Considering the
advantages and disadvantages of the available LAA
closure devices, we designed a novel holdfast device for
LAA obliteration devoid of these shortcomings.10
The aim of this study was to evaluate the biocom-
patibility of the proposed device and examine the
morphological and histological processes occurring in
the adjacent tissues after the implementation of the
device. We paid particular emphasis on the type and
extent of inflammatory reactions occurring during
proper tissue cicatrization. We also assessed the pos-
sible gross pathologies and side effects that could result
from the implantation of our device.
MATERIALS AND METHODS
Device Design
To occlude the LAA from the outside and thus
prevent the connection between the left atrium and the
appendage without damaging the surrounding tissue, a
special holdfast device was designed in cooperation
with the Technical University of Gdańsk, Poland. The
construction of the holdfast was the subject of a Patent
Cooperation Treaty, which is registered under No.
PCT/PL2014/000031. The device consisted of two
tubes connected with an elastic bow (Fig. 2). The
concept of operation for the device was based on the
idea that the tubes would press the LAA base, which
would lead to its closure and occlude the connection
between the LAA and left atrium (Fig. 2). Moreover,
the intention was that the device could be freely posi-
tioned around the LAA and could be easily adjusted
after implantation.
The whole unit was made monolithically using a 3D
printing method with Selective Laser Sintering (SLS)
technology with polyamide powder PA 2200 (PA 12),
which is a biostable polymer that is used in biomedical
engineering. The biocompatibility of the material was
certified according to ISO 10993-1.16 The polyamide
powder is widely used in clinical medicine and until
now has shown no carcinogenicity.26 Polyamides are
long-chain polymers with amide bonds that are the
result of the reaction of acids with amines. Due to a
good balance between properties (high strength and
rigidity, good chemical resistance, high long-term sta-
bility, good selectivity resolution and true to detail)
FIGURE 1. Photographs of human cadaveric heart specimens showing left atrial appendage (LAA). (a) The left lateral view on the
heart showing the location of the LAA. (b) Cross section through the left atrium (LA) and the LAA. Narrow left atrial appendage
ostium (LAAO) and rich trabeculations (T) within the LAA are visible, which are responsible for blood stasis and clot formation. MV
mitral valve, LV left ventricle, PA pulmonary artery, RV right ventricle.
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and its low price, they are one of the most common
polymers applied.17 Products made of PA 12 have
near-perfect chemical and thermal resistance, low
moisture absorption and high resistance to deforma-
tion. The SLS 3D printing technology was selected due
to its widespread availability and low production costs
which could allow future on-site 3D printing for
specific patient.
The dimensions of the clip were calculated, designed
and described by computer modelling (finite element
method) keeping in mind the stretch and thickness of a
human LAA, which is approximately 6 mm, and were
thus designed to have a clamping force of 36 N. This
force value was found to be advantageous for LAA
occlusion in a large canine model.13 From engineering
point of view, the target to achieve was a low stiffness
spring with a highly degressive characteristic of the
device. This was achieved by: choice of material (PA
2200 polyamide with Young’s modulus of 1500 MPa,
Poisson’s ratio of 0.38, tensile yield strength of 45 MPa
and elongation at break of 24%) and shifting the bow
crossection axis away from the device axis (which re-
sults in bending at an arm that grows as the spring is
deflected).
Choice of geometric parameter of the spring was
achieved by multivariant topology corrections in Finite
Element Method (FEM) calculations. FEM model in
ANSYS Workbench software was designed as sym-
metric half of the spring, one wall of left atrial ap-
pendage of width 1.5 mm (Young’s modulus 9 MPa,
Poisson’s ratio 0.4) and their interaction via contact
finite elements. Model load on holdfast device (sup-
ported on plane of symmetry) was deformation in Y
direction of the lower wall of the model up to 6 mm
(corresponding to whole spring deformation of
12 mm). As a result of multiple trials, a sufficiently
uniform stress distribution was achieved. This stress is
of high value, which might render stress relaxation
after a few months of device implantation, when irre-
versible changes in tissue occur and the pressure would
not be needed anymore. At maximum deflection of the
spring (limited by application tool geometry) of 10 mm
the device undergoes local plastic deformation, only in
flexible joint—connection the bow and tubes. The
maximum extension of the tubes was set to
10 mm—this value was enough to help with the
implementation process but would still not pose a
hazard to the structure of the device (Fig. 3).
In Vivo Animal Testing
After obtaining the end-product prototype, which
met all the necessary criteria of an LAA holdfast
(clamping force of 36 N, a size which would allow to
close the base of the LAA, the possibility of increased
spread of the clamping jaw up to 10 mm without
damaging the clamp), we conducted an in vivo inves-
tigation of its effectiveness and safety. This part of
study was conducted in collaboration with the Faculty
of Veterinary Medicine at Warmia and Mazury
University, and the experiments were performed in a
swine model. Two study groups were formed to assess
the reaction between the material of the holdfast and a
material with a well-known and documented local
reaction in the human body (polyester vascular pros-
thesis Vascutek Gelsoft Prosthesis, Terumo, Scotland,
UK):
FIGURE 2. Schematic image of the left atrial appendage (LAA) holdfast device. (a) Left lateral view on the heart with implanted
LAA holdfast device and a cross section through the LAA excluded from the left atrium (LA) by the holdfast device is showed.
Dimensions of the LAA holdfast device are reported in mm. (b) Technical drawing of the designed LAA holdfast device. LV left
ventricle, PA pulmonary artery.
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– Group I, had the standard, uncoated holdfast
device without additional materials applied
(Fig. 4a),
– Group II, had one tube of the holdfast device
coated with a vascular implant, Vascutek Gelsoft
Prosthesis, Terumo (Scotland, UK), which was
made of polyester (Fig. 4b).
This inquiry was consistent with the European
Standard pertaining to ‘‘Biological evaluation of
medical devices—Part 6. Test for local effects after
implantation’’ (ISO 10993-6:2007).15 All procedures
were executed with strict accordance with the recom-
mendations of the Guide for the Care and Use of
Laboratory Animals of the National Institutes of
Health. The protocol was approved by the Committee
on the Ethics of Animal Experiments of the Medical
University of Gdańsk, Poland (Permit Number: 42/
2013) and the Faculty of Veterinary Medicine at
Warmia and Mazury University, Poland (Permit
Number: 21/S/2013). All efforts were made to mini-
mize the suffering of the animals. The protocols for
anesthesia and animal sacrifice were also approved by
both Universities.
For the experiment, 30 swine (Sus scrofa f. domes-
tica, Great white Polish pig, 60% females, 17 weeks old)
were used. The animals came from one breed and had
an average body weight of 55.5 kg (range 55.0–60.0
kg). After 14 days of quarantine, the animals were
randomly divided into two study groups (15 swine in
each group) and subjected to device implantation.
Routine general anesthesia was used. Access to the
mediastinum was obtained via left thoracotomy. The
chest was opened at the fourth intercostal space
(Fig. 5a). All holdfast devices were sanitized in 0.5%
Aniosyme DD1 (Laboratories Anios, France) for a
period of 5 min and at a temperature of 20 C. After
drying the devices, they were sanitized in 100% ethy-
lene oxide at a temperature of 55 C for 60 min. The
holdfast devices were implanted after a minimum of
12 h of aeration. The application was made identically
in both groups, according to the previously established
procedure (Fig. 5b).10
On the 14th day after the surgical procedure, the
animals were subjected to euthanasia, except for four
animals from group II, which were subjected to a
prolonged incubation. To fulfill the EN ISO 10993-
6:2009 IDT recommendations for the prolonged
observation of the tissue reaction in the comparison
model, the incubation in these four swine lasted for 90
days.15 To perform the euthanasia, routine general
anesthesia was performed and pentobarbital sodium
(Euthasol vet, Le Vet B.V., Netherlands) was delivered
intravenously in a dose of 140 mg/kg of body weight.
Immediately after the animals’ euthanasia, hearts were
dissected in a routine manner, washed out of blood
and fixed by immersion in 4% paraformaldehyde
buffered solution for a 48 h period.
Postmortem Evaluation
The hearts were subjected to a macroscopic evalu-
ation and observed to see whether there was formation
of adhesions between the occluded LAA walls. They
FIGURE 3. Stress distribution in the holdfast device at (a) substantial deflection caused by a left atrial appendage of 6 mm in
thickness and (b) substantial deflection of 10 mm (maximum value, limited by application tool geometry).
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BRZEZIŃSKI et al.136
were also examined to evaluate the tissue reaction to
polyamide powder at the Pathomorphology Institute,
Medical University of Gdańsk, Poland. In all 30 swine
hearts, the efficacy of the LAA occlusion was checked
(this was determined by assessing the tightness in the
clamp line and the presence of the tissue concrescence).
Next, fragments of the left atrial wall with the appen-
dage and the novel holdfast device were sliced into
23.0 9 30.0 9 5.0 mm3 blocks. Each block consisted
of a LAA with an intersection through the holdfast
device. Next, the samples were subject of a standard
histological examination. In short, specimens were
subsequently dehydrated by administering appropriate
concentrations of ethanol alcohol and xylene and were
then embedded in paraffin. All paraffin blocks were cut
into 4.0 lm thick serial sections. The samples were
dyed with hematoxylin and eosin according to routine
procedure.
To assess the tissue reaction to the implanted LAA
device, the following were examined for each swine in
both study groups:
– hyperemia: 0—lack, 1—small degree, 2—medium
degree, 3—significant degree,
– intensity of chronic inflammatory infiltrate (mea-
sured by counting the number of lymphoid
mononuclear cells): 0—lack, 1—small degree,
2—medium degree, 3—significant degree of chronic
inflammatory infiltration,
FIGURE 4. Holdfast device (a) without additional materials
implanted in group I and (b) coated with a vascular graft
(polyester Vascutek Gelsoft Prosthesis, Terumo, Scotland,
UK) implanted in group II. (c) The side view on the holdfast
device. (d) Holdfast device positioned on the applicator with
opened clamping jaw.
FIGURE 5. Periprocedural photographs showing (a) access
site via left thoracotomy (the chest was opened at the fourth
intercostal space) and (b) implanted left atrial appendage
(LAA) holdfast device.
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– presence of purulent infiltration: 0—lack, 1—pre-
sent,
– presence of foreign-body giant cells: 0—lack,
1—present,
– and the degree of cicatrization: 0—lack, 1—small
degree, 2—medium degree, 3—significant degree.
Statistical Analysis
Categorical variables were expressed as counts and
percentages. The Shapiro–Wilk test was performed to
determine normal distribution. When comparing con-
tinuous variables between groups that had a normal
distribution, an independent t-test was used. Contin-
uous variables that did not exhibit a normal distribu-
tion were compared with a Mann-Whitney U test. All
dichotomous variables were compared using x2 anal-
ysis or Kolmogorov–Smirnov test. The sample size was
estimated assuming that to show difference between 10
and 50% in single parameter change requires at least
20 animals with 80% statistical power and a signifi-
cance level of 0.05 (two-sided test). Statistical analysis
was performed with STATISTICA 12.0 (StatSoft,
Tulsa, OK, USA). A two-sided p-value lower than 0.05
was considered statistically significant.
RESULTS
There were no perioperative deaths and a full
recovery with complete physiological activity was
observed in all animals. In all subjects, a complete
LAA occlusion was obtained. In both tested groups
(including swine with prolonged incubation time), the
surface of the atrium under a holdfast device was
smooth and shiny and lacked clots and the walls of the
LAA located between the holdfast device closely ad-
hered to each other. The line of the appendage wall’s
adhesion was not fully formed, and the left appendage
did not undergo total atrophy. On the surface between
and around the holdfasts, fibrous connective tissue was
visible (Fig. 6). Based on the macroscopic evaluation,
no crucial differences in tissue response to different
device tubes were observed.
Table 1 and Fig. 7 show the between-groups com-
parisons of all histological findings. No signs of hold-
fast material degeneration were observed in any study
group.
There were no signs of significant passive hyperemia
or purulent infiltration around the holdfast devices in
Group I. The atrial surface from the clamped side was
covered with a single layer of endothelial cells; fur-
thermore, there was mature granulation tissue and
chronic nonspecific inflammatory infiltrate composed
of lymphoid cells without foreign body giant cells, both
in-between and around the tubes of the holdfast de-
vices. Over large surface areas, granulation tissue was
partially replaced with collagenized fibrous tissue. The
inner side of an appendage was filled with organized
blood clots, whereas newly formed granulation tissue
characterized by fibroblast proliferation was visible on
the surface.
In Group II which was subject to 14 days of incu-
bation, there were no crucial differences observed in
the level of hyperemia (lack or small, p > 0.05), cica-
trisation (p > 0.05) or purulent infiltration (mainly
lack, p > 0.05) between both tubes of the holdfast
device (coated vs. not coated with arterial graft). We
observed significantly more intense chronic inflamma-
tory infiltrate and many more foreign-body giant cells
around the fragment of the holdfast devices supple-
mented with a polyester graft (Fig. 8, p < 0.05). Like
in Group I, no foreign-body giant cells around the
fragment of the uncoated polyamide holdfast device
was reported. When comparing histological features of
the tissue around the coated tube in Group II with
14 days of incubation to uncoated tubes in Group I,
the only observed difference was in the presence of
foreign-body giant cells (p < 0.0001). To summarize,
in Group I, connective tissue scar formation was
observed without a clear inflammatory reaction,
whereas in holdfast devices coated with a polyester
vascular graft (Group II), there was a clear influence of
this material on the heart tissue; a scar was formed
around the polyester graft, and there was chronic
inflammatory infiltrate with foreign-body giant cells
penetrating the material.
In the animals from Group II, which had a pro-
longed 90 days incubation time, there was similar in-
tense chronic inflammatory infiltration, however a
greater degree of scar collagenization and cicatrisation
was observed when compared to the standard 14 days
Group II swines (p < 0.05).
DISCUSSION
When new biomaterials are used in any living
organism, it is crucial to verify whether they can be
biocompatible with the surrounding tissues to prevent
any pathological postoperative reactions.11,12,25,28 Two
elements should be considered: biological safety and
biofunctionality. Firstly, this means the material
should be tested to ensure that it does not cause any
harm. Secondly, the material/device should be studied
to ensure its properties function as they were
designed.3,11 The host response to biomaterials has
been studied for decades.11,28,29 Recently, there has
been particular interest in the quest to finding a tech-
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nical solution of obliterating the LAA, by inserting a
device with biocompatible materials within the human
body. This idea has been a challenge for many scien-
tific centers.1,12,28,29 The point of contact between the
material and native tissue is the most important place
at which the intracellular sequence initiates the auto-
and paracrine response of the host’s tissue. Therefore,
the material’s surface structures, both spatial and
chemical, are crucial elements for reducing the unde-
sirable host immune response.27
In our previous study we have demonstrated the
safety and efficacy of the 3D printed novel LAA
exclusion device within an animal model, which
showed rapid closure times, reduced rates of bleeding,
tissue tearing and proper fibrous scar formation.10
Furthermore, we introduced the various possibilities
and novelties associated with the manufacturing
methods. Thanks to the use of 3D printing, our device
could reduce the time needed for elaborate design and
production. This technique could bring unique
opportunities to individualize each product depending
on the needs of the patient. Finally, the proposed
approach would be deemed acceptable in terms of
overall device cost.10 The estimated price of one 3D
print LAA holdfast device would come to about 50
Euro. Sterilization and packaging of one device would
cost about 5 Euro. This would be significantly lower
than the available devices for LAA exclusion, whose
costs vary from 2000 to 4000 Euro per set (e.g. Atri-
Clip LAA Exclusion System). Moreover, the devel-
oped LAA holdfast device would have a great
advantage over staplers that could be placed on the
base of the LAA. Unfortunately, the latter may dam-
age the tissue and interrupt the continuity of the left
atrial wall, a phenomenon which has not been
observed in printed holdfast devices. These devices
would also not be as flexible as the new device we are
proposing (since the staples cannot be repositioned).
This study emphasized the favorable biocompati-
bility of the polyamide powder (PA 2200) used in 3D
printing Selective Laser Sintering (SLS) technology
when compared to a well-known implantable material
in humans (Vascutek Gelsoft Prosthesis, Terumo,
Scotland, UK). No significant differences in terms of
hyperemia and scarring were observed in between both
materials, however more intense chronic inflammatory
infiltrate was present around the device coated with
polyester. The uncoated polyamide caused the forma-
tion of a connective tissue scar with no apparent
inflammatory reaction, but an inflammatory reaction
in the heart tissue was observed when it was covered
with polyester. The reaction to a foreign body was
connected to unspecific protein adsorption, the im-
mune response and the presence of inflammatory cells
under physiological conditions, and all of these chan-
ges were intended to protect and isolate the body from
a foreign invasion.11,25,29 The degree of the organism’s
immune reaction depends on a product’s properties,
including its structure, shape, chemical composition,
porosity and coarseness as well as the contact dura-
tion, material degradation and sterility.12,25 Therefore,
based on our results, we can clearly state that the
reported holdfast device meets all the biocompatibility
criteria specified in PN-EN ISO 10993-6_2009E rec-
ommendations.
There are several limitations to this preclinical
study. The study groups were relatively small, with
only four subjects with a maximum of 90 days incu-
bation. In addition, we did not analyze the effects of
the holdfast device on the serum biochemistry levels.
Thus, serum natriuretic peptide, troponins, creatine
kinase and inflammatory response proteins were not
measured. Such measurements could allow a better
holistic understanding of the body’s defense responses
and could assess the impact of the holdfast device on
the condition of the heart. Regardless, our data did not
FIGURE 6. A macroscopic view of the left atrial appendage (LAA) closed with the holdfast device in group II (one tube coated with
vascular implant). (a) The inner surface of the left atrium (LA) and (b) the intersection through the area of a holdfast device is
shown. (a) Black arrows indicate the line of atrial wall adhesion placed between tubes of holdfast device. (b) The white arrow
indicates the tube of holdfast device without and black arrow with a vascular implant. Red square indicates area showed in Fig. 8.
MV mitral valve, LV left ventricle.
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BRZEZIŃSKI et al.140
show any macroscopic or microscopic pathological
responses to the device and no clinical signs of heart
failure in all animals. The surface of the atrium under a
holdfast device was smooth and shiny and lacked clots,
atrophy or necrosis. Our study was performed exclu-
sively on healthy animals (with structurally unchanged
heart atria), and hence evaluation using animal model
with atrial fibrillation could be required to confirm our
results. Finally, the appendages of older patients with
various comorbidities might be more fragile and prone
to tissue damage/tearing. Those features also require
additional assessment in future studies.
To conclude, the current study has demonstrated
that the use of 3D-printing technology could be used to
design and produce an inexpensive alternative for
commercially available LAA exclusion devices. The
foreign body reaction of the LAA holdfast device
made of polyamide powder was found to be at a sta-
tistically insignificant level and was lower when com-
pared to the polyester graft. Our device fulfils the
criteria of biocompatibility to the highest degree,
which makes it a suitable material for manufacturing
LAA holdfast devices. This study proves that our
FIGURE 7. Column charts showing comparison of histological data between study groups.
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technology may be applied for quick, innovative and
individualized production of medical implants.
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Brzeziński, Leszek Dąbrowski and Jan Rogowski and
the patent owner is the JITMED LTD (Poland). This
does not alter our adherence to all the Current Medical
Research and Opinion policies on sharing data and
materials, as detailed online in the guide for authors.
The funders had no role in study design, data collec-
tion and analysis, decision to publish, or preparation
of the manuscript.
CONFLICT OF INTEREST
All authors have nothing to disclose.
OPEN ACCESS
This article is distributed under the terms of the
Creative Commons Attribution 4.0 International Li-
cense (http://creativecommons.org/licenses/by/4.0/),
which permits unrestricted use, distribution, and
reproduction in any medium, provided you give
appropriate credit to the original author(s) and the
source, provide a link to the Creative Commons li-
cense, and indicate if changes were made.
REFERENCES
1Almeida, M. J., W. B. Yoshida, L. Hafner, J. Sequeira, J.
H. dos Santos, A. P. B. Masseno, J. B. Moreno, and S. de
Lorena. Biomechanical and histologic analysis in aortic
endoprosthesis using fibrin glue. J. Vasc. Surg. 53:1368–
1374, 2011.
2Al-Saady, N. M., O. A. Obel, and A. J. Camm. Left atrial
appendage: structure, function, and role in thromboem-
bolism. Heart 82:547–554, 1999.
3Amorim, W. L., H. O. Costa, F. C. de Souza, M. G. de
Castro, and L. da Silva. Estudo experimental da resposta
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5Bartuś, K. Left atrial appendage occlusion procedures.
Polish J. Cardio-Thoracic Surg. 14:1–4, 2017.
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